Anorexia Nervosa - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 2 PAGES: 39

Anorexia Nervosa - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Anorexia Nervosa - Pipeline Review, H2 2011', provides an overview of the Anorexia Nervosa therapeutic pipeline. This report provides information on the therapeutic development for Anorexia Nervosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anorexia Nervosa. 'Anorexia Nervosa - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anorexia Nervosa.
- A review of the Anorexia Nervosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anorexia Nervosa pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anorexia Nervosa.
- Identify emerging players with potentially strong product portfolio and design effective counter-

More Info
									Anorexia Nervosa – Pipeline Review, H2 2011




                Anorexia Nervosa - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1457IDB

                                                                                          Publication Date: October 2011




Anorexia Nervosa – Pipeline Review, H2 2011                                                                      GMDHC1457IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Anorexia Nervosa – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
      Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Anorexia Nervosa Overview ..................................................................................................................................................................................... 6
Therapeutics Development ....................................................................................................................................................................................... 7
      An Overview of Pipeline Products for Anorexia Nervosa .................................................................................................................................... 7
Anorexia Nervosa Therapeutics under Development by Companies ......................................................................................................................... 9
Anorexia Nervosa Therapeutics under Investigation by Universities/Institutes .........................................................................................................10
Late Stage Products ................................................................................................................................................................................................12
      Comparative Analysis .......................................................................................................................................................................................12
Mid Clinical Stage Products .....................................................................................................................................................................................13
      Comparative Analysis .......................................................................................................................................................................................13
Early Clinical Stage Products ..................................................................................................................................................................................14
      Comparative Analysis .......................................................................................................................................................................................14
Anorexia Nervosa Therapeutics - Products under Development by Companies.......................................................................................................15
Anorexia Nervosa Therapeutics - Products under Investigation by Universities/Institutes ........................................................................................16
Companies Involved in Anorexia Nervosa Therapeutics Development ....................................................................................................................17
      Daiichi Sankyo Company, Ltd ...........................................................................................................................................................................17
Anorexia Nervosa - Therapeutics Assessment ........................................................................................................................................................18
      Assessment by Monotherapy Products .............................................................................................................................................................18
      Assessment by Combination Products ..............................................................................................................................................................19
      Assessment by Route of Administration ............................................................................................................................................................20
      Assessment by Molecule Type ..........................................................................................................................................................................22
Drug Profiles ...........................................................................................................................................................................................................24
      SUN11031 - Drug Profile...................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24
            Mechanism of Action...................................................................................................................................................................................24
            R&D Progress .............................................................................................................................................................................................24
      Kanglaite - Drug Profile .....................................................................................................................................................................................25
            Product Description ....................................................................................................................................................................................25
            Mechanism of Action...................................................................................................................................................................................25
            R&D Progress .............................................................................................................................................................................................25
      Seroquel - Drug Profile ......................................................................................................................................................................................26
            Product Description ....................................................................................................................................................................................26
            Mechanism of Action...................................................................................................................................................................................26
            R&D Progress .............................................................................................................................................................................................26
      Aripiprazole - Drug Profile .................................................................................................................................................................................27
            Product Description ....................................................................................................................................................................................27
            Mechanism of Action...................................................................................................................................................................................27
            R&D Progress .............................................................................................................................................................................................27
      Oxytocin - Drug Profile ......................................................................................................................................................................................28
            Product Description ....................................................................................................................................................................................28
            Mechanism of Action...................................................................................................................................................................................28
            R&D Progress ....................................................................................................
								
To top